VCNX - Vaccinex Short-Term Debt to Capital

Symbol and logo of brand Vaccinex, Inc (VCNX)

This daily price chart for Vaccinex, Inc. (VCNX) reflects metrics at 0.00, while the business faces stringent FDA oversight and patent restrictions. Vaccinex, Inc. (VCNX) is implementing advanced protein blocking methods for oncology and sclerosis therapies. Meanwhile, the scientific and technical infrastructure and partner plants are fully prepared for the mass production of synthesized molecules.

Current Liabilities to Capital: Vaccinex, Inc (VCNX) for 07/04/2022 - 12/28/2024

Summary analytical data breakdowns for vaccinex.com (VCNX)

- stock value and consensus price forecast:
Price Chart Vaccinex, Inc|VCNX - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Vaccinex Inc.|VCNX - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Vaccinex|VCNX - Total Stockholders' Equity|Market Value to Book Value Ratio vaccinex.com|VCNX - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Vaccinex, Inc.|VCNX - Long-Term Liabilities to Capital|Short-Term Debt to Capital Vaccinex|VCNX - Company Total Indebtedness|Debt to Book Value Vaccinex Inc.|VCNX - Long-Term Debt|Company Current Liabilities Vaccinex|Quick Ratio vaccinex.com
- company profitability and valuation multiples indicators:
VCNX - Net Financial Result
Initial company analysis:Vaccinex, Inc VCNX
Signature product of vaccinex.com

Finding a balance between operational risks and return on equity for Vaccinex, Inc. (VCNX) is complicated by geopolitical instability, which undermines international research and raw material logistics for cancer therapy; consequently, the dynamics of short-term loans to equity, reflecting the share of liabilities under one year within the capital structure, serve as a key indicator of the company's solvency and financial stability amid uncertainty.

Competitors of Vaccinex, Inc. (VCNX)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity Xencor, Inc.|Current Liabilities to Capital compasstherapeutics.com CMPX|Short-Term Debt to Capital REPL|Lyell (LYEL) - Short-Term Indebtedness to Equity|Innate Pharma, S.A. - Short-Term Debt to Equity Ratio|Pyxis Oncology Inc. (PYXS) - Current Liabilities to Capital|CGEN: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital IOBT (iobiotech.com)|STRO: Short-Term Debt to Capital|INKT - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Werewolf Therapeutics Inc.|Short-Term Debt to Equity Ratio Immix (IMMX)|Short-Term Debt to Equity ALX Oncology (ALXO)|Short-Term Debt to Equity Ratio Cue Biopharma Inc. CUE|PDS Biotechnology Corporation - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Sonnet BioTherapeutics Holdings, Inc. SONN|MAIA - Short-Term Debt to Equity|LIMN (Liminatus) - Short-Term Debt to Capital Ratio|lavatherapeutics.com (LVTX) - Short-Term Debt to Equity|Current Liabilities to Capital nextcure.com (NXTC)|Short-Term Debt to Equity Ratio LPTX|INTS - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio SNSE (Sensei Biotherapeutics)|Short-Term Loans to Capital Ratio TOVX|Short-Term Debt to Capital GRTS (Gritstone bio)|Ratio of Short-Term Indebtedness to Capital KA|NexImmune - Short-Term Debt to Capital|Current Liabilities to Capital Turnstone Biologics|Harpoon Tx (HARP) - Short-Term Debt to Equity